Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
GLP-1 Gut Side Effects: What a Review Found
A narrative review summarizes gastrointestinal effects of GLP-1 and dual GIP/GLP-1 medicines and the limits of class-wide claims.
Novo's Hengrui Obesity-Pill Deal Explained
Novo has licensed an early-stage oral obesity candidate from Hengrui. Here is what the deal does and does not show.
Semaglutide and inflammatory monocytes
A 16-person study linked semaglutide with lower inflammatory monocytes and bone-marrow imaging changes, but it cannot prove cause and effect.
Semaglutide's modeled impact in Canada
A Canadian model projected broad semaglutide effects across conditions, costs and productivity, but its results are scenario estimates, not trial outcomes.
Semaglutide in forebrain organoids
A human-organoid study links semaglutide to less cholesterol-related neural stress, but it is not evidence of an Alzheimer's treatment.
Semaglutide in Pediatric Craniopharyngioma
A 20-patient retrospective series links semaglutide with lower BMI in adolescents with craniopharyngioma-related obesity, but cannot prove causation.
Tirzepatide and NAION: New Record
A new French journal record names tirzepatide and NAION, but its no-abstract PubMed entry cannot establish clinical details or causation.
A Real-World Tirzepatide Cost Study
A claims-and-laboratory study compared persistence, outcome thresholds, and a defined cost-per-responder measure in US type 2 diabetes care.
New amylin agonists for obesity and T2D
Zenagamtide, eloralintide and CagriSema have early to late-stage results in obesity and type 2 diabetes. Their evidence is not interchangeable.
GLP-1 Marketing and the Lifestyle Message
A new report describes a shift in GLP-1 marketing. The medical context, access questions, and limits still matter.
GLP-1 and SGLT2 therapy in CKD
A large matched cohort study linked GLP-1 plus SGLT2 therapy with lower kidney and cardiovascular outcome rates in CKD. It cannot prove causation.
Incretin injections vs intensified insulin
A 2026 review found lower hypoglycaemia and weight with incretin-based injections versus intensified insulin, but the average HbA1c edge was small.